Clinical trial · Observational
Remote Assessment of Physical Function
Remote Assessment of Physical Function in Older Cancer Survivors
NCT04339959CI-TRIAL-00077446completedResults postedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The primary objective is to evaluate the validity and reliability of using videoconferencing to assess physical performance tests self-administered by older cancer survivors in their own homes. This remote assessment will be compared to the traditional face-to-face (i.e., in-person) assessment and to accelerometer data.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer Survivors | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Remote Assessment of Physical Function | Other | — | UNRESOLVED |
| Remote Assessment of Physical Function with Direct Observation | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (4)
- label
- Phase I
- description
- First, we will test proof-of-concept that participants will be able to follow the testing protocol and use the tablet computer to communicate with the investigator (10-12 participants). The test protocol will be refined based on what is learned after a minimum of 10 participants. We anticipate no more than 12 participants needed for this phase.
- interventionNames
- Other: Remote Assessment of Physical Function with Direct Observation
- label
- Phase II
- description
- Next, 10-20 new participants will be enrolled to evaluate the validity of videoconference vs. face-to-face assessment (i.e., direct observation) of physical performance. Communication will occur between the remote assessor and the participant. The direct observer will not communicate directly to the participant, unless there is a safety issue. After completing 10 participants without a major change in the test protocol, we will proceed to the next phase.
- interventionNames
- Other: Remote Assessment of Physical Function with Direct Observation
- label
- Phase III
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 60 Years
Show eligibility criteria text
Inclusion Criteria: * Residence in New Mexico * Previous diagnosis of cancer, completed primary treatment (surgery, radiation, chemotherapy), and not currently being treated for a recurrence. * Mild-to-moderate physical functional impairment (≥2 functions limited a lot or limited a little on the Short Form 36-item Physical Function Subscale) * Able to speak, read, \& understand English * Participating in less than 120 minutes per week of moderate-to-vigorous intensity physical activity * Living independently and capable of walking 3 blocks without stopping to rest. * Availability of a family member or friend to be present (for safety) during remote assessment of performance tests (Phases III and IV only) * No severe impairments or pre-existing medical limitations for engaging in daily light-intensity physical activity (e.g., severe orthopedic conditions, pending hip/knee replacement, chronic vertigo, dementia) * No severe hearing or vision deficits that would inhibit communication with the research team via videoconferencing and tablet use. * Willing to use a tablet computer and videoconferencing software to communicate with a study team member during the assessment. * Enough space (14 feet by 3 feet) to safely conduct the physical function tests. * Not at high risk for falls
References
Publications (1)
- DERIVEDBlair CK, Harding E, Herman C, Boyce T, Demark-Wahnefried W, Davis S, Kinney AY, Pankratz VS. Remote Assessment of Functional Mobility and Strength in Older Cancer Survivors: Protocol for a Validity and Reliability Study. JMIR Res Protoc. 2020 Sep 1;9(9):e20834. doi: 10.2196/20834. PMID 32769075